Managing erectile dysfunction in heart failure

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 13, Issue 1, 2013, Pages 125-134

  Giagulli, V A ^a   Moghetti, P ^b   Kaufman, J M ^c   Guastamacchia, E ^a   Iacoviello, M ^d   Triggiani, V ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b Urology Clinic   (Italy)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

(PDE 5) therapy; Erectile dysfunction; Heart Failure; Phosphodiesterase type

Indexed keywords

APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIURETIC AGENT; DOXORUBICIN; SILDENAFIL; SPIRONOLACTONE; TADALAFIL; TESTOSTERONE; THIAZIDE DIURETIC AGENT; VARDENAFIL; YOHIMBINE;

ATHEROSCLEROTIC PLAQUE; CARDIOMYOPATHY; DISEASE ASSOCIATION; DYSPEPSIA; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; ENERGY EXPENDITURE; ERECTILE DYSFUNCTION; FLUSHING; GYNECOMASTIA; HEADACHE; HEART FAILURE; HUMAN; METABOLIC EQUIVALENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN CONSUMPTION; PSYCHOLOGICAL ASPECT; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT;

ADULT; AGED; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HEART FAILURE; HUMANS; MALE; MIDDLE AGED;

EID: 84875866388     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530311313010015     Document Type: Review

References (140)

1. Lindau, S.T. and Gavrilova, N. (2010) Sex, health and years of sexually active live gained due to good heath: evidence form two US population based cross sectional surveys of ageing. B.M.J., 9, 340, c810.
2. Corona, G.; Lee, D.M.; Forti, G.; O'Connor, D.B.; Maggi, M.; O'Neill, T.W.; Pendleton, N.; Bartfai, G.; Boonen, S.; Casanueva, F.F.; Finn, J.D.; Giwercman, A.; Han, T.S.; Huhtaniemi, I.T.; Kula, K.; Lean, M.E.; Punab, M.; Silman, A.J.; Vanderschueren, D.; Wu, F.C. and EMAS Study Group. (2010) Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J.S.M., 7, 1362-1380.
3. Hall, S.A.; Shackelton, R.; Rosen, R.C. and Araujo, A.B. (2010) Sexual activity, erectile dysfunction, and incident cardiovascular event. Am. J. Cardiol., 105, 192-197.
4. Hatzimouratis, K.; Amar, E.; Eardley, I.; Giuliano, F.; Hatzichristou, D.; Montorsi, F.; Vardi, Y.; Wespes, E. and European Association of Urology. (2010) Guidelines on male sexual dysfunction: erectile disfuction and premature ejaculation. Eur. Urol., 57, 804-814.
5. Schwarz, E.R.; Rastogi, S.; Kapur, V.; Sulemanjee, N. and Rodriguez, J.J. (2006) Erectile dysfunction in heart failure patients. J. Am. Coll. Cardiol., 48, 1111-1119.
6. Rastogi, S.; Rodriguez, J.J.; Kapur, V. and Schwarz, E.R. (2005) Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem. Int. J. Impot. Res., 17(Suppl 1), S25-S36.
7. Chew, K.K.; Bremner, A.; Stuckey, B.; Earle, C. and Jamrozik, K. (2009) Sex life after 65: how does erectile dysfunction affect ageing and elderly men? Aging Male, 12, 41-46.
8. Schwarz, E.R.; Rastogi, S.; Kapur, V.; Sulemanjee, N. and Rodriguez, J.J. (2006) Erectile dysfunction in heart failure patients. J. Am. Coll. Cardiol., 48, 1111-1119.
9. Goldstein, I. (2000) The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am. J. Cardiol., 86, 41F-45F.
10. Corona, G.; Monami, M.; Rastrelli, G.; Aversa, A.; Tishova, Y.; Saad, F.; Lenzi, A.; Forti, G.; Mannucci, E. and Maggi, M. (2011) Testosterone and metabolic syndrome: a meta-analysis study. J. Sex Med., 8, 272-283.
11. Baraghoush, A.; Phan, A.; Willix, R.D. Jr. and Schwarz, E.R. (2010) Erectile dysfunction as a complication of heart failure. Cur. Heart Fail. Rep., 7, 194-221.
12. Schwarz, E.R.; Rastogi, S.; Kapur, V.; Sulemanjee, N. and Rodriguez, J.J. (2006) Erectile dysfunction in heart failure patients. J. Am. Coll. Cardiol., 48, 1111-1119.
13. Mandras, S.A.; Urber, P.A. and Mhera, M.R. (2007) Sexual activity and chronic heart failure. Mayo. Clin. Proc., 82, 1203-1210.
14. Bohlen, J.G.; Held, J.P.; Sanderson, M.O. and Patterson, R.P. (1984) Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Arch. Intern. Med., 144, 1745-1748.
15. Nemec, E.D.; Mansfield, L. and Kennedy, J.W. (1976) Heart rate and blood pressure responses during sexual activity in normal males. Am. Heart. J., 92, 274-277.
16. Cremers, B.; Kjellstrom, B.; Sudkamp, M. and Bohm, M. (2002) Hemodynamic monitoring during sexual intercourse and physical exercise in a patient with chronic heart failure and pulmonary hypertension. Am. J. Med., 112, 428-430.
17. Apostolo, A.; Vignati, C.; Brusoni, D.; Cattadori, G.; Contini, M.; Veglia, F.; Magrì, D.; Palermo, P.; Tedesco, C., Doria, E.; Fiorentini, C.; Montorsi, P. and Agostoni, P. (2009) Erectile dysfunction in heart failure: correlation with severity, exercise preformance, comorbility, and heart failure tratment. J. Sex Med., 6, 2795-2805.
18. Steinke, E.E. (2005) Intimacy needs and chronic illness: strategies for sexual counseling and self-management. J. Gerontol. Nurs., 31, 40-50.
19. Dahabresh, I.J. and Paulus, J.K. (2011) Association of Episodic Physical and Sexual Activity With Triggering of Acute Cardiac Events: systematic review and meta-analysis. JAMA, 305, 1225-1233.
20. Anker, S.D.; Chua, T.P.; Ponionwski, P.; Harrington, D.; Swan, J.W.; Kox, W.J.; Poole-Wilson, P.A. and Coats, A.J. (1997) Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation, 96, 526-534.
21. Kontoleon, P.E., Anastasiou-Nana, M.I.; Papapetrou, P.D.; Alexopoulos, G.; Ktenas, V.; Rapti, A.C.; Tsagalou, E.P. and Nanas, J.N. (2003) Hormonal profile in patients with congestive heart failure. Int. J. Cardiol., 87, 179-183.
22. Ruige, G.B.; Mahmoud, A.M.; De Bacquer, D. and Kaufman, J.M. (2011) Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart, 97, 870-875.
23. Pugh, P.J.; Jones, T.H.; West, J.N.; Jones, T.H. and Channer, K.S. (2004) Testosterone treatment for men with chronic heart failure. Heart, 90, 445-447.
24. Jankowska, E.A.; Biel, B.; Majda, J.; Szklarska, A.; Lopuszanska, M.; Medras, M.; Anker, S.D., Banasiak, W.; Poole-Wilson, P.A. and Ponikowski, P. (2006) Anabolic deficiency in men with chronic heart failure prevalence and detrimental impact on survival. Circulation, 114, 1829-1837.
25. Bocchi, E.A.; Carvalho, V.O. and Guimaraes, G. (2008) Inverse correlation between testosterone and ventricolar ejection fraction, hemodynamics and exercise capacity in heart failure patients with erectile dysfunction. Inter. Braz. J. Urol., 34, 302-312.
26. Morelli, A.; Filippi, S.; Mancina, R.; Luconi, M.; Vignozzi, L., Marini, M.; Orlando C., Vannelli, G.B.; Aversa, A.; Natali, A.; Forti, G.; Giorgi, M.; Jannini, E.A.; Ledda, F. and Maggi, M. (2004) Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology, 145, 2253-2263.
27. Wingard, C.J.; Johnson, J.A.; Holmes, A. and Prikosh, A. (2003) Improved erectile function after Rho-kinase inhibition in a rat castrate model of erectile dysfunction. Am. J. Physiol. Regul. Integr. Comp. Physiol., 284, R1572-R1579.
28. Toma, M.; McAlister, F.A.; Coglianese, E.E.; Vidi, V.; Vasaiwala, S.; Bakal, J.A.; Armstrong, P.W. and Ezekowitz, J.A. (2012) Testosterone Supplementation in Heart Failure: A Meta-Analysis. Circulation, 5, 315-231.
29. Pelle, A.J.M.; Gidron, Y.Y.; Szabo, B.M. and Denollet, J. (2008) Psychological predictors of prognosis in chronic heart failure. J. Card. Fail., 14, 341-350.
30. Freedland, K.E.; Carney, R.M. and Rich, M.W. (2011) Impact of depression on prognosis of heart failure Heart Fail. Clin., 7, 11-21.
31. Albert, N.M.; Fonarow, G.C.; Abraham, W.T.; Gheorghiade, M.; Greenberg, B.H.; Nunez, E.; O'Connor, C.M.; Stough, W.G.; Yancy, C.W. and Young, J.B. (2009) Depression and clinical autcomes in heart failure: an OTIMIZE-HF analysis. Am. J. Med., 122, 366-373.
32. Goldstein, I. (2000) The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am. J. Cardiol., 86, 41F-45F.
33. Goodlin, S.J. (2010) Sadness in heart failure: what is a clinician to do? J. Am. Col. Card., 56, 700-701.
34. Pena, F.M.; Modenesi Rde, F.; Piraciaba, M.C.; Marins, R.M.; Souza, L.B.; Barcelos, A.F. and Soares Jda, S. (2011) Prevalence and variable predictive of depressive symptoms in patients hospedalized for heart failure. Cardiol. J., 28, 18-25.
35. Seidman, S.N. and Roose, S.P. (2000) The relationship between depression and erectile dysfunction. Curr. Psychiatry. Rep., 2, 201-205.
36. Majani, G.; Pierobon, A.; Giardini, A.; Callegari, S.; Opasich, C.; Cobelli, F. and Tavazzi, L. (1999) Relationship between physiological profile and cardiological variables in chronic heart failure: the role of patient subjectivity. Eur. Heart J., 20, 1579-1586.
37. Friedman, S. (2000) Cardiac disease, anxiety and sexual functioning. Am. J. Cardiol., 86, 46F-50F.
38. Jiang, W.; Krishman, R.; Kuchibhatia, M.; Cuffe, M.S.; Martsberger, C.; Aria, R.M. and O'Connor, C.M. (2011) Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am. J. Cardiol., 107, 545-551.
39. Pizzi, C.; Rutlies, A.W.; Costa, G.M.; Fontana, F.; Mezzeretti, A. and Manzoli, L. (2011) Meta-analysis of selective serotonine reuptake inhibitors in patients with depression and coronary heart diseases. Am. J. Cardiol., 107, 972-979.
40. Herman, J.B.; Brotman, A.W.; Pollack, W.E.; Falk, M.H., Biedeman, J. and Rosenbaum, J.F. (1990) Fluoxetine induced sexual dysfunction. J. Clin. Psychiatry, 51, 25-27.
41. Miner, M.N. (2011) Erectile dysfunction: a harbinger or cosequence: does its detection lead to a window of curability? J. Androl., 32, 125-134.
42. Kaya, C.; Uslu, Z. and Karaman, I. (2006) Is endothelial function impaired in erectile dysfunction patients? Int. J. Impot. Res., 18, 55-60.
43. Chew, K.K.; Bremmer, S.; Jamrozik, K.; Earle, C. and Stuckey, B. (2008) Male erection dysfunction and cardiovascular disease: is there an intimate nexus? J. Sex Med., 5, 928-934.
44. Thompson, I.M.; Tangen, C.M.; Goodman, P.J.; Probstfield, J.L.; Moinpour, C.M. and Coltman, C.A. (2005) Erectile dysfunction and subsequent cardiovascular diseases. JAMA, 294, 2996-3002.
45. Inman, B.A.; Sauver, J.L.; Jacobson, D.J.; McGree, M.E.; Nehera, A.; Lieber, M.M.; Roger, V.L. and Jacobson, S.J. (2009) A population-based, longitudinal study of erectile dysfunction and future coronary artery diseases. Mayo. Clinc. Proc., 84, 108-113.
46. Montorsi, P.; Ravagnani, P.M.; Galli, S.; Colonia, A.; Briganti, A.; Werba, J.P. and Montorsi, F. (2006) Association between erectile dysfuntion and coronary artery disesase. Matching the right target with the right test in the raight patient. Eur. Urol., 50, 721-731.
47. Gazzaruso, C.; Gardanetti, D.; De Amicis, E.; Bertone, G.; Falcone, C.; Geroldi, D.; Fratino, P.; Solerte, S.B. and Garzanti, A. (2004) A repatioinship between erectile dysfuntion and silent myocadial ischemia in apparently uncomplicated type 2 diabetes patients. Circulation, 110, 22-26.
48. Ma. R.C., So, W.Y.; Yang, X.; Yu, L.W.; Kong, A.P.; Ko, G.T.; Chow, C.C., Cockram, C.S.; Chan, J.C. and Tong, P.C. (2008) Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J. Am. Coll. Cardiol., 51, 2045-2050.
49. Baraghoush, A.; Phan, A.; Willix, R.D. Jr. and Schwarz, E.R. (2010) Erectile dysfunction as a Complication of Heart Failure. Curr. Heart Fail. Rep., 7, 194-201.
50. Vural, A.; Agacdiken, A.; Celikyurt, U.; Culha, M.; Kahraman, G.; Kozdag, G. and Ural, D. (2011) Effect of cardiac resynchronization therapy on libido and erectile dysfunction. Clin. Cardiol., 34, 437-441.
51. Buffum, J. (1986) Pharmosexology update:prescrptions drugs and sexual function. J. Psychoactive Drugs, 18, 87-106.
52. Böhm, M.; Baumhäkel, M.; Teo, K.; Sleight, P.; Probstfield, J.; Gao, P.; Mann, J.F.; Diaz, R.; Dagenais, G.R.; Jennings, G.L.; Liu, L.; Jansky, P.; Yusuf, S. and ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. (2010) Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation, 121, 1439-1446.
53. Dusing, R. (2005) Sexual dysfunction in male patients with hypertension: influence of hypertihypetensive drugs. Drug, 65, 773-786.
54. Menard, J. (2004) The 45-year story of the development of an antialdosterone more specific than spironolactone. Mol. Cell Endocrinol., 217, 45-52.
55. Morris, S.A.; Hatcher, H.F. and Reddy, D.K. (2006) Digoxin therapy for heart failure: an update. Am. Fam. Physician, 74, 613-618.
56. Neri, A.; Zukerman, Z.; Aygen, M.; Lidor, Y. and Kaufman, H. (1987) The effect of long-term administration of digoxin on plasma androgens and sexual dysfunction. J. Sex Marital Ther., 13, 58-63.
57. Gupta, S.; Salimpour, P.; Saenz de Tejada, I.; Daley, J.; Gholami, S.; Daller, M.; Krane, R.J.; Traish, A.M. and Goldstein, I. (1998) A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity. J. Urol., 159, 1529-1536.
58. Klein, L.; O'Connor, C.M.; Gattis, W.A.; Zampino, M.; De Luca, L.; Vitarelli, A.; Fedele, F. and Gheorghiade, M. (2003) Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am. J. Cardiol., 91, 18F-40F.
59. Silvestri, A.; Galetta, P.; Cerquetani, E.; Marazzi, G.; Patrizi, R.; Fini, M. and Rosano, G.M. (2003) Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur. Heart J., 24, 1928-1932.
60. Baumhäkel, M.; Schlimmer, N.; Büyükafsar, K.; Arikan and O.; Böhm, M. (2008) Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein Eknockout mice. J. Pharmacol. Exp. Ther., 325, 818-823.
61. Angulo, J.; Wright, H.M.; Cuevas, P.; González-Corrochano, R.; Fernández, A.; Cuevas, B.; La Fuente, J.M.; Gupta, S. and Sáenz de Tejada, I. (2010) Nebivolol dilates human penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signalling. J. Sex Med., 7, 2681-2697.
62. Cordero, A.; Bertomeu-Martínez, V.; Mazón, P.; Fácila, L.; Bertomeu-González, V.; Conthe, P. and González-Juanatey, J.R. (2010) Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc. Ther., 28, 15-22.
63. DiBianco, R. (1991) A large-scale trial of captopril for mild to moderate heart failure in the primary care setting. Clin. Cardiol., 14, 676-682.
64. Dusing, R. (2003) Effect of the angiotensin II antagonist valsartan on sexual function in the primary care setting. Blood Press. Suppl., 2, 29-34.
65. Schlimmer, N.; Kratz, M.; Böhm, M. and Baumhäkel, M. (2011) Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterolinduced atherosclerosis. Br. J. Pharmacol., 163, 804-814.
66. Baumhäkel, M.; Schlimmer, N.; Kratz, M.; Hackett, G.; Jackson, G. and Böhm, M. (2011) Cardiovascular risk, drugs and erectile function--a systematic analysis. Int. J. Clin. Pract., 65, 289-298.
67. Ignarro, L.J. (1999) Nitric oxide: a unique endogenous signalling molecule in vascular biology. Biospip. Rep., 19, 51-71.
68. Bredt, D.S. and Snyder, S.H. (1994) Nitric oxide: a physiologic messenger molecule. Annu. Rev. Biochem., 63, 175-195.
69. Levine, A.B.; Punihaole, D. and Levine, T.B. (2012) Characterization of the role of nitric oxide and its clinical applications. Cardiology, 122, 55-68.
70. Duplain, H., Burcelin, R.; Sartori, C.; Cook, S.; Egli, M.; Lepori, M.; Vollenweider, P.; Pedrazzini, T.; Nicod, P.; Thorens, B. and Scherrer, U. (2001) Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation, 104, 342-345.
71. Lima, B.; Forrester, M.T.; Hess, D.T. and Stamler, J.S. (2010) Snitrosylation in cardiovascular signaling. Circ. Res., 106, 633-646.
72. Shenouda, S.M.; Widlansky, M.E.; Chen, K.; Xu, G.; Holbrook, M.; Tabit, C.E.; Hamburg, N.M.; Frame, A.A.; Caiano, T.L.; Kluge, M.A.; Duess, M.A.; Levit, A.; Kim, B.; Hartman, M.L.; Joseph, L.; Shirihai, O.S. and Vita, J.A. (2011) Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation, 124, 444-453.
73. Lee, J.; Giordano, S. and Zhang, J (2012) Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem. J., 441, 523-540.
74. Glagov, S.; Weisenberg, E.; Zarins, C.K.; Stankunavicius, R. and Kolettis, G.J. (1987) Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med., 316, 1371-1375.
75. Welt, F.G. and Simon, D.I. (2001)Atherosclerosis and plaque rupture. Catheter. Cardiovasc. Interv., 53, 56-63.
76. Bonetti, P.O.; Lerman, L.O. and Lerman, A. (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol., 23, 168-175.
77. Montorsi, P.; Ravagnani, P.M. and Galli S. (2009)The triad endothelial dysfunction, cardiovascular diseases, and erectile dysfunction: clinical implications Eur. Urol., 9, 58-66.
78. Böger, R.H.; Bode-Böger, S.M. and Frölich, J.C. (1996) The Larginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis, 127, 1-11.
79. Smith, C.J.; Sun, D.; Hoegler, C.; Roth, B.S.; Zhang, X.; Zhao, G.; Xu, X.B.; Kobari, Y.; Pritchard, K. Jr; Sessa, W.C. and Hintze, T.H. (1996) Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ. Res., 78, 58-64.
80. Vlachopoulos, C.; Aznaouridis, K.; Ioakeimidis, N.; Rokkas, K.; Vasiliadou, C.; Alexopoulos, N.; Stefanadi, E.; Askitis, A. and Stefanadis, C. (2006) Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur. Heart J., 27, 2640-2648.
81. Becker, A.J.; Uckert, S.; Stief, C.G.; Truss, M.C.; Hartmann, U. and Jonas, U. (2001) Systemic and cavernosal plasma levels of endothelin (1-21) during different penile conditions in healthy males and patients with erectile dysfunction. World J. Urol., 19, 371-376.
82. Rossoni, G.; Manfredi, B.; De Gennaro Colonna, V.; Berti, M.; Guazzi, M. and Berti, F. (2007) Sidenafil reduces L-NAMEinduced severe hypertension and worsering of myocardial ischaemia-reperfusion damage in the rat. Br. J. Pharmacol., 150, 567-576.
83. Medina, M.; Walker, C.; Steinke, E.E.; Wright, D.W.; Mosack, V. and Farhoud, M.H. (2009) Sexual concerns and sexual counselling in heart failure. Prog. Cardiovasc. Nurs., 24, 141-148.
84. Riegel, B.; Moser, D.K.; Powell, M.; Rector, T.S. and Havranek, E.P. (2006) Nonpharmacologic care by heart failure experts. J. Card. Fail., 12,149-153.
85. Dahabreh, I.J. and Paulus, J.K. (2011)Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis. JAMA, 305, 1225-1233.
86. rd; Cheitlin, M.; Debusk, R.; Fonseca, V.; Ganz, P.; Goldstein, I.; Guay, A.; Hatzichristou, D.; Hollander, J.E.; Hutter, A.; Katz, S.; Kloner, R.A.; Mittleman, M.; Montorsi, F.; Montorsi, P.; Nehra, A.; Sadovsky, R. and Shabsigh, R. (2005) Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am. J. Cardiol., 96, 85M-93M.
87. Hunt, S.A.; Abraham, W.T.; Chin, M.H.; Feldman, A.M.; Francis, G.S.; Ganiats, T.G.; Jessup, M.; Konstam, M.A.; Mancini, D.M.; Michl, K.; Oates, J.A.; Rahko, P.S.; Silver, M.A.; Stevenson, L.W. and Yancy, C.W. 2009 focused update incorporated into the ACC/AHA 2005 (2009) Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 119, e391-e479.
88. McMurray, JJ.; Adamopoulos, S.; Anker, S.D.; Auricchio, A.; Böhm, M.; Dickstein, K.; Falk, V.; Filippatos, G.; Fonseca, C.; Gomez-Sanchez, M.A.; Jaarsma, T.; Køber, L.; Lip, G.Y.; Maggioni, A.P.; Parkhomenko, A.; Pieske, B.M.; Popescu, B.A.; Rønnevik, P.K.; Rutten, F.H.; Schwitter, J.; Seferovic, P.; Stepinska, J.; Trindade, P.T.; Voors, A.A.; Zannad, F. and Zeiher, A.; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax J.J.; Baumgartner, H.; Ceconi, C.; Dean, V.; Deaton, C.; Fagard, R.; Funck-Brentano, C.; Hasdai, D.; Hoes, A.; Kirchhof, P.; Knuuti, J.; Kolh, P.; McDonagh, T.; Moulin, C.; Popescu, B.A.; Reiner, Z.; Sechtem, U.; Sirnes, P.A.; Tendera, M.; Torbicki, A.; Vahanian, A.; Windecker, S.; McDonagh, T.; Sechtem, U.; Bonet, L.A.; Avraamides, P.; Ben Lamin, H.A.; Brignole, M.; Coca, A.; Cowburn, P.; Dargie, H.; Elliott, P.; Flachskampf, F.A.; Guida, G.F.; Hardman, S.; Iung, B.; Merkely, B.; Mueller, C.; Nanas, J.N.; Nielsen, O.W.; Orn, S.; Parissis, J.T.; Ponikowski, P. and ESC Committee for Practice Guidelines. (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail., 14, 803-869.
89. Meldrum, D.R., Gambone, J.C.; Morris, M.A.; Esposito, K.; Giugliano, D. and Ignarro, L.J. (2012) Lifestyle and metabolic approaches to maximizing erectile and vascular health. Int. J. Impot. Res., 24, 61-68.
90. Goldstein, I.; Lue, T.F.; Padma-Nathan, H.; Rosen, R.C.; Steers, W.D. and Wicker, P.A. (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med., 338, 1397-1404.
91. Klotz, T.; Sachse, R.; Heidrich, A.; Jockenhövel, F.; Rohde, G.; Wensing, G.; Horstmann, R. and Engelmann, R. (2001) Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J. Urol., 19, 32-39.
92. Porst, H.; Padma-Nathan, H.; Giuliano, F.; Anglin, G.; Varanese, L. and Rosen, R (2003) Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology, 62, 121-125.
93. Aversa, A.; Bruzziches, R.; Pili, M. and Spera, G. (2006) Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr. Pharm. Des., 12, 3467-3484.
94. Ravipati, G.; McClung, J.A.; Aronow, W.S.; Peterson, S.J. and Frishman, W.H. (2007) Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol. Rev., 15, 76-86.
95. Bender, A.T. and Beavo, J.A. (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev., 58, 488-520.
96. Lin, C.S.; Lin, G.; Xin, Z.C. and Lue, T.F. (2006) Expression, distribution and regulation of phosphodiesterase 5. Curr. Pharm. Des., 12, 3439-3457.
97. Loughney, K.; Hill, T.R.; Florio, V.A.; Uher, L.; Rosman, G.J. Wolda, S.L.; Jones, B.A.; Howard, M.L.; McAllister-Lucas, L.M.; Sonnenburg, W.K., Francis, S.H.; Corbin, J.D.; Beavo, J.A. and Ferguson, K. (1998) Isolation adn characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene, 216, 139-147.
98. Corbin, J.D.; Francis, S.H. and Webb, D.J. (2002) Phosphodiesterase type 5 as a phamacological target in erectile dysfunction. Urology, 60, 4-11.
99. Corbin, J.D. and Francis, S.H. (2002) Pharmacology of phosphodiesterase 5 inhibitors. Inter. J. Clin. Pract., 56, 453-459.
100. Das, A.; Xi, L. and Kukreja, R.C. (2005) Phosphodiesterase-5 inhibitor Sildenafil precondition adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J. Biol. Chem., 280, 12944-12955.
101. Zhu, B.; Zhang, L.; Alexeyev, M.; Alvarez, D.F.; Strada, S.J. and Stevens, T. (2009) Type 5 phosphodiesterase expression is a critical determinant of the endotelial cell angiogenic phenotype. Am. J. Physiol. Lung Cell Mol. Physiol., 296, L220-228.
102. Lincoln, T.M.; Wu, X.; Sellak, H.; Dey, N. and Choi, C.S. (2006) Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase. Front. Biosci., 113, 56-67.
103. Kass, D.A.; Champion, H.C. and Beavo, J.A. (2007) Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ. Res., 101, 1084-1095.
104. Corbin, J.D.; Beasley, A.; Blount, M.A. and Francis, S.H. (2005) High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem. Biophys. Res. Commun., 334, 930-938.
105. Forfia, P.R.; Lee, M.; Tunin, R.S.; Mahmud, M.; Champion, H.C. and Kass, D.A. (2007) Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J. Am. Coll. Cardiol., 49, 1079-1088.
106. Guazzi, M. (2008) Sildefanil and phoshodiesterase-5 inhibitors for heart failure. Curr. Heart Fail. Rep., 5, 110-114.
107. Nagendran, J.; Archer, S.L.; Soliman, D.; Gurtu, V.; Moudgil, R.; Haromy, A.; St Aubin, C.; Webster, L.; Rebeyka, I.M.; Ross, D.B.; Light, P.E.; Dyck, J.R. and Michelakis, E.D. (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation, 116, 238-248.
108. Vlachopoulos, C.; Terentes-Printzios, D.; Ioakeimidis, N.; Rokkas, K. and Stefanadis, C. (2009) PDE5 inhibitors in non-urological conditions. Curr. Pharm. Des., 15, 3521-3539.
109. Michelakis, E.; Tymchak, W.; Lien, D.; Webster, L.; Hashimoto, K. and Archer, S. (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation, 105, 2398-2403.
110. Lepore, J.J.; Maroo, A.; Pereira, N.L.; Ginns, L.C.; Dec, G.W.; Zapol, W.M.; Bloch, K.D. and Semigran, M.J. (2002) Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am. J. Cardiol., 90, 677-680.
111. Pérez, N.G.; Piaggio, M.R.; Ennis, I.L.; Garciarena, C.D.; Morales, C.; Escudero, E.M.; Cingolani, O.H.; Chiappe de Cingolani, G.; Yang, X.P. and Cingolani, H.E. (2007) Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension, 49, 1095-1103.
112. Giannetta, E.; Isidori, A.M.; Galea, N.; Carbone, I.; Mandosi, E.; Vizza, C.D.; Naro, F.; Morano, S.; Fedele, F. and Lenzi, A. (2012) Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation, 125, 2323-2333.
113. Takimoto, E.; Champion, H.C.; Li, M.; Belardi, D.; Ren, S.; Rodriguez, E.R.; Bedja, D.; Gabrielson, K.L.; Wang, Y. and Kass, D.A. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med., 11, 214-222.
114. Guazzi, M. (2008) Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. Circ. Heart Fail., 1, 272-280.
115. Pomara, G.; Morelli, G.; Pomara, S.; Taddei, S.; Ghiadoni, L.; Dinelli, N.; Travaglini, F.; Dicuio, M.; Mondaini, N.; Salvetti, A. and Selli, C. (2004) Cardiovascular parameter changes in patient with erectile dysfunction using pde-5 inhibithors: a study with sildenafil and vardenafil. J. Androl., 25, 625-629.
116. DeBusk, R.F.; Pepine, C.J.; Glasser, D.B.; Shpilsky, A.; DeRiesthal, H. and Sweeney, M. (2004) Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am. J. Cardiol., 93, 147-153.
117. Katz, S.D.; Parker, J.D.; Glasser, D.B.; Bank, A.J.; Sherman, N.; Wang, H. and Sweeney, M. (2005) Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am. J. Cardiol., 95, 36-42.
118. Webster, L.J.; Michelakis, E.D.; Davis, T. and Archer, S.L. (2004) Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch. Intern. Med., 164, 514-520.
119. Freitas, D.; Athanazio, R.; Almeida, D.; Dantas, N. and Reis, F. (2006) Sildenafil improves quality of life in men with heart failure and erectile dysfunction. Int. J. Impot. Res., 18, 210-212.
120. Al-Ameri, H. and Kloner, R.A. (2009) Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. Int. J. Impot. Res., 21, 149-157.
121. Jackson, G.; Boon, N.; Eardley, I.; Kirby, M.; Dean, J.; Hackett, G.; Montorsi, P.; Montorsi, F.; Vlachopoulos, C.; Kloner, R.; Sharlip, I. and Miner, M. (2010) Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int. J. Clin. Pract., 64, 848-857.
122. Fox, K.M.; Thadani, U.; Ma, P.T.; Nash, S.D.; Keating, Z.; Czorniak, M.A.; Gillies, H.; Keltai, M and CAESAR I (Clinical American and European Studies of Angina and Revascularization) investigators. (2003) Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur. Heart J., 24, 2206-2212.
123. Vardi, Y.; Bulus, M.; Reisner, S.; Nassar, S.; Aboud, L.; Sprecher, E. and Gruenwald, I. (2003) Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular. Eur. Urol., 43, 544-551.
124. Bocchi, E.A.; Guimarães, G., Mocelin, A.; Bacal, F.; Bellotti, G. and Ramires, J.F. (2002) Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation, 106, 1097-1103.
125. Hirata, K.; Adji, A.; Vlachopoulos, C. and O'Rourke, M.F. (2005) Effect of sildenafil on cardiac performance in patient with heart failure. Am. J. Cardiol., 96, 1436-1440.
126. Katz, D.S.; Balidemaj, K.; Homma, S.; Wu, H.; Wang, J. and Maybaum, S. (2000) Acute type-5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilatation in patient with cronic heart failure. J. Am. Coll. Cardiol., 36, 845-851.
127. Lewis, G.D.; Lachmann, J.; Camuso, J.; Lepore, J.J.; Shin, J.; Martinovic, M.E., Systrom, D.M.; Bloch, K.D. and Semigran, M.J. (2007) Sildenafil improves exercise haemodynamics and oxigen uptake in patient with sistolic heart failure. Circulation, 115, 59-66.
128. Lewis, G.D.; Shah, R.; Shahzad, K.; Camuso, J.M.; Pappagianopoulos, P.P.; Hung, J.; Tawakol, A.; Gerszten, R.E.; Systrom, D.M.; Bloch, K.D. and Semigran, M.J. (2007) Sildenafil improves exercise capacity and quality of life in patients with sistolic heart failure and secondary pulmonary hypertension. Circulation, 116, 1555-1562.
129. Al-Hesayen, A.; Floras, J.S. and Parker, J.D. (2006) The effect of intravenous sildenafil on haemodinamics and cardiac sympathetic activity in cronic human heart failure. Eur. J. Heart Fail., 8, 864-868.
130. Behling, A.; Rohde, L.E.; Colombo, F.C.; Goldraich, L.A., Stein, R. and Clausell, N. (2008) Effect of 5'-phosphodiesterase fourweek long inhibition with sildenafil in patient with cronic heart failure: a double-blind placebo-controlled clinical trial. J. Card. Fail., 14, 189-197.
131. Guazzi, M.; Samaja, M.; Arena, R.; Vicenzi, M. and Guazzi, M.D. (2007) Long-term use of sildenafil in the therapeutic management of heart failure. J. Am. Coll. Card., 50, 2136-2144.
132. Mittleman, M.A., Maclure, M. and Glasser, D.B. (2005) Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am. J. Cardiol., 96, 443-446.
133. Jackson, G.; Kloner, R.A.; Costigan, T.M.; Warner, M.R. and Emmick, J.T. (2004) Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J. Sex Med., 1, 161-167.
134. Giuliano, F.; Jackson, G.; Montorsi, F.; Martin-Morales, A. and Raillard, P. (2010) Safety of sildenafil citrate: review of 67 doubleblind placebo-controlled trials and the postmarketing safety database. Inter. J. Clin. Pract., 64, 240-255.
135. Rendell, M.S.; Raifer, J.; Wicker, P.A. and Smith, M.D. (1999) Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA, 281, 421-426.
136. Vardi, M. and Nini. A. (2007) Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes. A Cochrane Database Syst. Rev., CD002187.
137. Guay, A.T.; Perez, J.B.; Jacobson, J. and Newton, R.A. (2001) Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic rick factors. J. Androl., 22, 793-797.
138. Dula, E.; Bukofzer, S.; Perdok, R.; George, M.; Apomorphine, S.L. and Study Group. (2001) Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erctile dysfunction. Eur. Urol., 39, 558-553.
139. Jackson, G.; Rosen, R.C.; Kloner, R.A. and Kostis, J.B. (2006) The second Princeton consensus on sexual dysfunction and cardiac rick: new guidelines for sexual medicine. J. Sex Med., 3, 28-36.
140. Carson, C.C.; Mulcahy, J.J. and Govier, F.E. (2000) Efficacy, safety and patient satisfaction outcomes of AMS 700CX infltable penis prothesis: results of a long-term multicenter study. AMS 700CX Study Group. J. Urol., 164, 376-380.